Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

RVTY shares jumped 9.1% to $140.19 after the company highlighted AI-driven demand for research tools, an improved order backlog, and its planned acquisition of Human Cell Design. Management guided to quarterly EPS of $1.28, representing 8.5% year-over-year growth, and revenue of $702.56 million, up 0.5% from the prior year.

The rally follows positive commentary on how artificial intelligence is fueling demand for RVTY's research instruments. The Human Cell Design acquisition adds strategic capability to the company's life sciences portfolio, though financial terms were not disclosed.

One headwind emerged in analyst sentiment: consensus EPS estimates have been revised marginally lower over the past 30 days, according to Zacks Investment Research. This downward revision could cap further upside despite the strong single-day performance.

The guidance suggests modest top-line growth paired with better margin expansion, given the 8.5% earnings growth outpacing the 0.5% revenue increase.